# Vivolight

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vivolight

- Industry: Medical Devices & Equipment
- Headquarters: Shenzhen, China
- Website: www.vivolight.cn
- Total disclosed funding: $14M
- Latest round: Series E (May 26, 2026)
- Investors on record: 13

## About

Based in Shenzhen, China, Shenzhen Vivolight Medical Device & Technology Co., Ltd., dba Vivolight, operates as a manufacturer of minimally invasive interventional laser diagnosis and treatment devices.  It has established an R&D center in Xi’an, China. In April 2020, the company's optical coherence tomography (OCT) system obtained the approval of NMPA and achieved commercialization. In December 2021, the Multimodality OCT System was approved by National Medical Products Administration (NMPA). In December 2021, its Multimodality OCT System was approved by NMPA.

In May 2026, Vivolight closed a round of series E funding co-led by China-US Green Yangtze River Delta and Efung Capital with participation from Boc Private Equity Firm and Huiyu Private Equity Fund Management (Huzhou).

Vivolight focuses on the research and development and manufacturing of minimally invasive interventional diagnostic and therapeutic medical devices utilizing medical laser technology. The company's products can be categorized into Intravascular OCT Imaging Systems that combines vulnerable plaque detection, physiology assessment, and calcium assessment to guide treatment strategy, and patient care devices such as vein finders and head-mounted AR vascular visualization device. The products' applications include cardiovascular and peripheral vascular diseases, and others.

The company generates revenue from developing and providing diagnostic and therapeutic medical devices.

The company will use the series E funding for the global commercialization of its core products, as well as the research, development, registration, and clinical advancement of its innovative pipeline, further solidifying its strategic layout in the field of intelligent interventional procedures.

## Funding rounds

- Series E, May 26, 2026 — Efung Capital, Huiyu Private Equity Fund Management (Huzhou), China-US Green Yangtze River Delta, Boc Private Equity Firm
- Series D, Sep 16, 2022, $14M — Hong Shan, Casstar Capital, Huajin Lingchuang Fund Management, China New Town (Beijing) Investment Fund Management, Fosun Health Capital
- Series B, May 1, 2017 — Rays Venture Capital
- Series A, Jul 21, 2016 — Beijing Cezheng Investment Management, Rays Venture Capital
- Angel, Feb 1, 2014 — Xike Angel Fund, Casstar Capital, Sangel Capital

## Investors

- Xike Angel Fund (https://capitalatlas.ai/funds/xike-angel-fund) — Angel
- Casstar Capital (https://capitalatlas.ai/funds/casstar-capital) — Angel, Series D
- Sangel Capital (https://capitalatlas.ai/funds/sangel-capital) — Angel
- Beijing Cezheng Investment Management — Series A
- Rays Venture Capital (https://capitalatlas.ai/funds/rays-venture-capital) — Series A, Series B
- Hong Shan — Series D
- Huajin Lingchuang Fund Management (https://capitalatlas.ai/funds/huajin-lingchuang-fund-management) — Series D
- China New Town (Beijing) Investment Fund Management — Series D
- Fosun Health Capital (https://capitalatlas.ai/funds/fosun-health-capital) — Series D
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series E
- Huiyu Private Equity Fund Management (Huzhou) (https://capitalatlas.ai/funds/huiyu-private-equity-fund-management-huzhou) — Series E
- China-US Green Yangtze River Delta — Series E
- Boc Private Equity Firm (https://capitalatlas.ai/funds/boc-private-equity-firm) — Series E